Medication info
Empacombi Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Empacombi Tablet 5/850 mg (Empagliflozin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Aprogen Biologics Co., Ltd.
Appearance
White, oval-shaped, biconvex film-coated tablet with a yellow tint
Packaging
10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202201334 · Approved 2022.04.04 · Insurance code 645210990

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Ingredients

Manufacturer
Aprogen Biologics Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Poor blood sugar control
  • type 2 diabetes
  • cardiovascular disease
View approved original text

This drug is used in combination with empagliflozin and metformin to help control blood sugar in adults with type 2 diabetes, alongside diet and exercise therapy. It is particularly effective for patients who have difficulty controlling blood sugar or have cardiovascular disease, so it is important to refer to relevant specialist guidelines during treatment. This drug helps improve blood sugar management, thereby aiding in diabetes treatment.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended dose is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's current metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their previous doses of empagliflozin and metformin. When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose, take it as soon as you remember. However, do not take twice the dose at one time; in this case, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is required for patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. In these patients, the starting dose of metformin is 500 mg or 850 mg once daily, so treatment should be initiated with the individual single-ingredient products empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see Precautions for Use, 2. Do not administer to the following patients, item 2)). Elderly Patients In patients aged 75 years or older, consider renal function and the risk of volume depletion.

Precautions

This drug is used for the treatment of diabetes, with the active ingredients empagliflozin and metformin hydrochloride working to lower blood sugar. Caution is required when taking this medication, as a rare side effect known as severe lactic acidosis may occur. Lactic acidosis is a condition where lactic acid accumulates excessively in the blood, posing harm to the body and potentially life-threatening in severe cases. Additionally, when used in conjunction with insulin or sulfonylurea drugs, hypoglycemia, or abnormally low blood sugar levels, may rarely occur, so caution is advised. This medication should not be administered to patients with moderately to severely impaired renal function or those experiencing acute kidney issues, severe infections, heart failure, or acute myocardial infarction. When undergoing tests that use iodinated contrast agents, the medication should be discontinued for a certain period before and after the examination, and it should only be resumed once normal renal function is confirmed. It is safer not to use this medication in pregnant women or those who may become pregnant, as well as nursing mothers. Patients should be cautious of fluid loss and dehydration symptoms while taking this medication, particularly elderly patients or those with cardiovascular disease, who should take extra care. This drug can reduce vitamin B12 levels, so it is advisable to check vitamin B12 status during long-term use. There is a risk of hypoglycemia; therefore, missing meals, irregular eating, excessive exercise, or alcohol consumption should be approached cautiously. This medication may increase the risk of urinary and genital infections; if any infection symptoms occur, immediate consultation with healthcare professionals is necessary. Patients planning for surgery should discontinue this medication 48 hours prior and resume it only after confirming normal renal function following the procedure. In cases of overdose, the risk of lactic acidosis may increase significantly; therefore, immediate medical treatment is required, and hemodialysis may be necessary. Regular monitoring of blood sugar and renal function should occur during the use of this medication, and any unusual symptoms should be reported to healthcare providers promptly. The safety and effectiveness of this medication have not been established in children, so it should not be used in this population.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
Show 160 more
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • itching
  • rash
  • hives
  • erythema and angioedema
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • increased blood creatinine
  • decreased glomerular filtration rate
  • vaginismus
  • vulvitis
  • balanitis
  • perineal necrosis
  • decreased fluid volume
  • hypotension
  • dehydration
  • low blood pressure
  • decreased blood volume
  • orthostatic hypotension
  • syncope
  • vitamin B12 deficiency and reduction
  • ketoacidosis
  • lactic acidosis
  • headache
  • dizziness
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • lower gastrointestinal bleeding
  • appendiceal abscess
  • appendicitis
  • meningitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • positional dizziness
  • sensory loss
  • amnesia
  • facial paralysis
  • drowsiness
  • asthenia
  • chest discomfort
  • chest pain
  • fever
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight loss
  • urinary stones
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urination
  • vulvar pruritus
  • benign prostatic hyperplasia
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermoid cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • macular fibrosis
  • ocular discomfort
  • eye congestion
  • pathological myopia
  • retinal detachment
  • retinal crystals
  • retinal vein occlusion
  • serous retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • falls
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • road traffic accident
  • splenic injury
  • sternum fracture
  • angina
  • palpitations
  • Prinzmetal angina
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodule
  • unstable angina

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from exposure to air and moisture. It is important to maintain storage temperatures between 1 to 30 degrees Celsius at room temperature to extend the medication's effectiveness.

Appearance and packaging

Appearance

White, oval-shaped, biconvex film-coated tablet with a yellow tint

Package unit

10 tablets/box [(10 tablets/PTP x 1)], 60 tablets/box [(10 tablets/PTP x 6)], 30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.